We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+8.88%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$4.2B
AUM Growth
+$12M
Cap. Flow
-$165M
Cap. Flow %
-3.93%
Top 10 Hldgs %
34.34%
Holding
127
New
6
Increased
36
Reduced
16
Closed
4

Top Buys

Rank Stock Value
1
HUM icon
Humana
HUM
+$21.9M
2
BSX icon
Boston Scientific
BSX
+$14M
3
MRUS
Merus
MRUS
+$10.5M
4
AGL icon
Agilon Health
AGL
+$8.99M
5
BPMC
Blueprint Medicines
BPMC
+$8.35M

Top Sells

Rank Stock Value
1
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$111M
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$40.3M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$25.9M
4
PEN icon
Penumbra
PEN
+$20.7M
5
UNH icon
UnitedHealth
UNH
+$19.6M

Sector Composition

Rank Sector Weight
1 Healthcare 97.12%
2 Consumer Staples 1.04%
3 Industrials 0.9%
4 Financials 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ADAP
101
DELISTED
Adaptimmune Therapeutics
ADAP
$2.58M 0.06%
2,787,845
– –
FULC icon
102
Fulcrum Therapeutics
FULC
$288M
$2.4M 0.06%
727,673
– –
KNTE
103
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$2.26M 0.05%
746,973
– –
IMGN
104
DELISTED
Immunogen Inc
IMGN
$2.13M 0.05%
+112,620
New +$1.33M
NVTA
105
DELISTED
Invitae Corporation
NVTA
$1.87M 0.04%
1,650,495
-1,590,930
-49% -$2.01M
EPIX
106
DELISTED
ESSA Pharma
EPIX
$1.79M 0.04%
663,317
+138,373
+26% +$406K
SYRE icon
107
Spyre Therapeutics
SYRE
$9.25B
$1.54M 0.04%
136,556
– –
CGEN icon
108
Compugen
CGEN
$220M
$1.47M 0.04%
1,289,990
– –
GMDA
109
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
$1.38M 0.03%
715,023
-1,629,626
-70% -$2.8M
GOSS icon
110
Gossamer Bio
GOSS
$87.7M
$1.32M 0.03%
1,100,274
– –
VINC
111
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$1.16M 0.03%
44,586
– –
APLT
112
DELISTED
Applied Therapeutics
APLT
$999K 0.02%
780,791
– –
SPRO icon
113
Spero Therapeutics
SPRO
$72.4M
$971K 0.02%
669,533
– –
ALT icon
114
Altimmune
ALT
$583M
$788K 0.02%
223,255
– –
NKTX icon
115
Nkarta
NKTX
$177M
$726K 0.02%
331,571
-61,818
-16% -$272K
TPST icon
116
Tempest Therapeutics
TPST
$16.9M
$681K 0.02%
41,247
-22,111
-35% -$556K
BCEL
117
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$355K 0.01%
362,530
– –
TLPH icon
118
Talphera
TLPH
$73.7M
$351K 0.01%
316,460
– –
NUVB.WS
119
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$22.2K ﹤0.01%
134,028
– –
ETNB
120
CALL
DELISTED
89bio
ETNB
– –
-164,500
Closed -$2.51M
VERV
121
DELISTED
Verve Therapeutics
VERV
– –
-558,837
Closed -$8.06M
RXDX
122
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
– –
-1,031,550
Closed -$111M
AMYT
123
DELISTED
Amryt Pharma plc American Depositary Shares
AMYT
– –
-1,325,625
Closed -$19.3M
1 2 3 4
5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q2 2023 Portfolio in Review

As of Q2 2023, Rock Springs Capital Management held 127 positions worth $4.2B, up 0.29% from $4.19B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Rock Springs Capital Management withdrew a net $165M in Q2 2023, closing 4 positions and reducing 16 holdings. Its most notable exit was Prometheus Biosciences, Inc. Common Stock, an estimated $111M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 97% a quarter earlier, followed by Consumer Staples and Industrials.

Against the trend, Rock Springs Capital Management opened a new position in Boston Scientific worth $14.5M.

  • Rock Springs Capital Management's largest Q2 2023 buy was Boston Scientific: 267,500 shares worth $14.5M.
  • Rock Springs Capital Management added most to Humana in Q2 2023, an estimated $21.9M increase.
  • Rock Springs Capital Management's biggest Q2 2023 reduction was Madrigal Pharmaceuticals, cutting an estimated $40.3M.
  • Rock Springs Capital Management fully exited Prometheus Biosciences, Inc. Common Stock in Q2 2023, selling an estimated $111M.
  • Rock Springs Capital Management's ten largest holdings make up 34% of its $4.2B portfolio in Q2 2023.
  • Rock Springs Capital Management opened 6 new positions and closed 4 in Q2 2023.
  • Rock Springs Capital Management's portfolio value rose 0.29% quarter-over-quarter to $4.2B.

Based on Rock Springs Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.